Related Experiment Video
Updated: May 16, 2026

Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform
Published on: November 30, 2016
Down-Regulation of miR-149-5p Regulates Colon Mucosal Epithelial Cell Function by Targeting IGF2BP1 to Alleviate
Xiaotong He1, Guoyu Chen1, Lingmei Feng1
1Department of Gastroenterology, Shanghai Pudong New Area People's Hospital, Shanghai, China.
Background:
Irritable bowel syndrome (IBS) increases the risk of depression and damages the body, but there is no ideal treatment. However, aberrant expression of miRNAs in gastrointestinal diseases holds promise for the treatment of IBS. The aim of this study was to investigate how miR-149-5p regulates IBS by affecting the function of colonic mucosal epithelial cells.
Methods:
We examined miR-149-5p and IGF2BP1 levels in colonic tissue from clinical patients. The mice model of IBS was established by acetic acid (AA) enema, and NCM460 was induced using LPS in order to establish a cellular model. Measurement of fecal weight and water content in mice evaluated the model. miR-149-5p, IGF2BP1, IL-1β, and IL-6 levels were detected by qRT-PCR. The targeting relationship between miR-149-5p and IGF2BP1 was detected by dual-luciferase reporter gene assay, and cell proliferation was examined by CCK-8. Elisa was used to detect D-LA concentration.
Key Results:
miR-149-5p levels were up-regulated in the colon of patients with IBS, whereas the opposite was true for IGF2BP1 levels. AA enemas exacerbated the degree of diarrhea in mice, but diarrhea and inflammation were less severe in miR-149-5p-/- mice. miR-149-5p negatively regulates IGF2BP1. IGF2BP1 partially reversed the enhanced proliferation and inflammatory suppression of NCM460 cells caused by silencing miR-149-5p.
Conclusions And Inferences:
Inhibition of miR-149-5p protects colonic mucosal epithelial cells and alleviates IBS by negatively regulating IGF2BP1.
More Related Videos
Related Concept Videos
Irritable Bowel Syndrome
Irritable Bowel Syndrome I: Introduction
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
Drugs for Treatment of Constipation-Predominant IBS
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Inflammatory Bowel Disease II: Ulcerative Colitis
Renewal of Intestinal Stem Cells

